期刊文献+

多发性骨髓瘤相关周围神经病变治疗进展 被引量:5

Advances in the treatment of multiple myeloma-associated peripheral neuropathy
下载PDF
导出
摘要 多发性骨髓瘤(MM)属于浆细胞恶性克隆增殖性疾病,该病主要特点是免疫球蛋白的大量分泌,从而造成器官和组织的损伤。MM发病率逐年升高,目前是血液系统第二大最常见的恶性肿瘤,发病以中老年人为主。周围神经病变(PN)是MM患者常见的并发症之一,随着该病诊治水平的升高,原发病及相关治疗药物引起的PN发生率也逐渐增加。目前尚无针对多发性骨髓瘤患者周围神经病变(MMPN)的治疗手段。因此,对于MMPN的发病机制及相关预防及治疗药物的研究成为目前研究热点。
作者 张新莲 孙云霞 牛宇娟 张鹏鹏 Zhang Xinlian;Sun Yunxia;Niu Yujuan;Zhang Pengpeng
出处 《甘肃医药》 2020年第11期976-979,共4页 Gansu Medical Journal
基金 兰州市卫生健康科技发展项目(项目编号:2019-004)。
  • 相关文献

参考文献3

二级参考文献31

  • 1Delforge M, Blade J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues[J]. Lancet Oncol, 2010, 11(11) :1086-1095.
  • 2Mohty B, E1-Cheikh J, Yakoub-Agha I, et al. Peripheral neuropathy and new treatments for multiple myeloma:baekground and practical recommendations [ J ]. Haematologiea, 2010, 95 (2) :311-319.
  • 3Sonnevcld P, Jongen JL. Dealing with neuropathy in plasma-cell dyscrasias [ J ]. Hematology Am Soc Hematol Educ Program, 2010, 2010:423-430.
  • 4Morawska M, Grzasko N, Kostyra M, et al. Therapy-related peripheral neuropathy in multiple myeloma patients [ J/OL ]. Hematol Oucol, 2014 [ 2015-06-09]. http ://onlinelibrary. wiley. com/doi/10. 1002/hon. 2149/epdf. [ published online ahead of print November 14, 2014].
  • 5Dimopnulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma:subanalysis of the phase 3 VISTA study [ J ]. Eur J Haematol, 2011, 86( 1 ) :23-31.
  • 6Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase Ⅲ APEX trial in relapsed multiple myeloma: impact of a dose- modification guideline[J]. Br J Haematol, 2009, 144(6) :895- 903.
  • 7Hrusovsky I, Emmerich B, von Rohr A, et al. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multieenter survey in Germany and Switzerland [ J ]. Oncology, 2010, 79(3-4):247-254.
  • 8Petrucci MT, Giraldo P, Corradini P, et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma[ J]. Br J Haematol, 2013, 160 (5) :649-659.
  • 9Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy [ J ]. J Clin Oneol, 2009, 27(21 ) :3518-3525.
  • 10Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma [J]. Leukemia, 2012, 26(4) :595-608.

共引文献52

同被引文献50

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部